COST-EFFECTIVENESS OF THE CELL-BASED QUADRIVALENT VERSUS THE STANDARD EGG-BASED QUADRIVALENT INFLUENZA VACCINE IN GERMANY.

被引：0
|
作者：
Cai, R. [1 ]
Eichner, M. [2 ]
Schwehm, M. [3 ]
Rajaram, S. [4 ]
Joaquin, F. M. Q. [5 ]
Lamotte, M. [6 ]
机构：
[1] IQVIA, Amsterdam, Netherlands
[2] Univ Tubingen, Tubingen, Germany
[3] ExploSYS GmbH, Leinfelden Echterdingen, Germany
[4] Seqirus, Maidenhead, Berks, England
[5] Seqirus, Summit, NJ USA
[6] IQVIA, Zaventem, Belgium
来源：
VALUE IN HEALTH | 2020年 / 23卷
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PIN32
引用
收藏
页码：S548 / S548
页数：1
相关论文
共 50 条
  • [41] Cost-Effectiveness of Adjuvanted Quadrivalent Influenza Vaccine for Adults over 65 in France
    Paccalin, Marc
    Gavazzi, Gaetan
    Berkovitch, Quentin
    Leleu, Henri
    Moreau, Romain
    Ciglia, Emanuele
    Burlet, Nansa
    Mould-Quevedo, Joaquin F.
    VACCINES, 2024, 12 (06)
  • [42] COST-EFFECTIVENESS OF QUADRIVALENT INFLUENZA VACCINE FOR NATIONAL IMMUNIZATION PROGRAM IN SOUTH KOREA
    Shin, G.
    Choi, S.
    Lim, J.
    Kang, D.
    Bae, E.
    Choi, M. J.
    NhoJy
    Song, J. Y.
    Cheong, H. J.
    Yun, J. W.
    Kim, Y.
    Lim, E.
    VALUE IN HEALTH, 2017, 20 (09) : A789 - A789
  • [43] Cost-effectiveness of the adjuvanted quadrivalent influenza vaccine for older adults in South Korea
    Song, Youngji
    Shim, Eunha
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2024, 20 (01)
  • [44] Comparison of vaccine effectiveness against influenza hospitalization of cell-based and egg-based influenza vaccines, 2017-2018
    Bruxvoort, Katia J.
    Luo, Yi
    Ackerson, Bradley
    Tanenbaum, Hilary C.
    Sy, Lina S.
    Gandhi, Ashesh
    Tseng, Hung Fu
    VACCINE, 2019, 37 (39) : 5807 - 5811
  • [45] The Cost-Effectiveness of a Quadrivalent Human Papillomavirus Vaccine in Taiwan
    Dasbach, Erik J.
    Insinga, Ralph P.
    Yang, Yuh Cheng
    Pwu, Raoh-Fang
    Lac, Christina
    Elbasha, Elamin H.
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2008, 9 (03) : 459 - 466
  • [46] QUADRIVALENT HPV VACCINE IN ARGENTINA: COST-EFFECTIVENESS ANALYSIS
    Caporale, J.
    Alcaraz, A.
    Rey-Ares, L.
    Pichon-Riviere, A.
    Bardach, A.
    Augustovski, F.
    Klein, K.
    Tatti, S.
    VALUE IN HEALTH, 2014, 17 (03) : A273 - A273
  • [47] COST-EFFECTIVENESS COMPARISON OF QUADRIVALENT VERSUS TRIVALENT INFLUENZA VACCINES IN THE UNITED STATES
    Pitman, R. J.
    Nagy, L. D.
    Antonova, E.
    Scott, D. A.
    VALUE IN HEALTH, 2013, 16 (03) : A90 - A91
  • [48] The cost-effectiveness of a quadrivalent human papillomavirus vaccine in Hungary
    Dasbach, E.
    Elbasha, E.
    Insinga, R.
    Nagy, L.
    VALUE IN HEALTH, 2007, 10 (06) : A443 - A443
  • [49] COST EFFECTIVENESS OF QUADRIVALENT INFLUENZA VACCINE OVER TRIVALENT VACCINE IN FRANCE
    Duru, G.
    Carrat, F.
    Pribil, C.
    Bricaire, F.
    Pujol, P.
    Robert, J.
    Lafuma, A.
    VALUE IN HEALTH, 2014, 17 (07) : A678 - A678
  • [50] Modelling the Economic Impact of influenza Vaccine Programs with the Cell-Based Quadrivalent Influenza Vaccine and Adjuvanted Trivalent Influenza Vaccine in Canada
    Nguyen, Van Hung
    Roy, Bertrand
    VACCINES, 2022, 10 (08)
12345